SAN FRANCISCO--(BUSINESS WIRE)--Fluxion Biosciences today announced the commercial launch of its BioFlux platform, which provides automated biofilm analysis for disease research and drug discovery applications. Biofilms are bacterial or fungal layers that form in the body and are extremely resistant to antibiotics. Biofilms are implicated in a number of diseases including cystic fibrosis and pneumonia.
